Silence Therapeutics announced it will be acquired by Merck KGaA for approximately $1.3 billion in cash, representing a 130% premium to its recent closing price. This acquisition significantly boosts Silence Therapeutics' stock price and provides Merck KGaA with access to its siRNA technology and rare disease pipeline.
Silence Therapeutics (SLN) announced its acquisition by Merck KGaA for $1.3 billion in cash, valuing SLN at $20 per ADS, a 130% premium. This news sent SLN shares skyrocketing, reflecting the immediate positive impact for its shareholders. For Merck KGaA (MKKGY, MKGAF), the deal strengthens its rare disease pipeline with Silence's siRNA technology and experimental drug divesiran, targeting polycythemia vera. This is a strategic move for Merck KGaA to expand its specialty and rare disease focus, building on previous acquisitions. Short-term, SLN shareholders benefit from the substantial premium, while Merck KGaA faces integration challenges and the long-term success of divesiran. The key opportunity for traders was the immediate arbitrage play on SLN following the announcement, while Merck KGaA's stock reaction will depend on investor perception of the strategic value and cost of the acquisition.